Clinical pharmacogenomics and concept of personalized medicine

Journal of Medical Biochemistry

Volumn 31, Issue 4, 2012, Pages 281-286

  Babić, Nikolina ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

direct to consumer testing; personalized medicine; pharmacogenomics

Indexed keywords

ABACAVIR; AZATHIOPRINE; CARBAMAZEPINE; CELECOXIB; CETUXIMAB; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DNA; DRUG METABOLIZING ENZYME; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; MERCAPTOPURINE; PANITUMUMAB; TIOGUANINE; WARFARIN;

ADVERSE DRUG REACTION; ARTICLE; BIPOLAR DISORDER; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COLON CANCER; CONSUMER; DRUG EFFICACY; DRUG INFORMATION; DRUG LABELING; DRUG MANUFACTURE; DRUG METABOLISM; DRUG SCREENING; DRUG SENSITIVITY; DRUG TRANSPORT; EPILEPSY; FAMILY HISTORY; GENE DELETION; GENE INSERTION; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA; LUNG CANCER; PAIN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRESCRIPTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84876520314     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-012-0021-2     Document Type: Article

References (30)

1. Over-the-Counter DNA Testing: Wave of the Future or Waste of Money? http://abcnews.go.com/Health/Wellness/dna-screening-home-coming-walgreens/story? id=10614580#.T7PsS-hAaO5 (Accessed May 15, 2012).
2. HR. 5440 (111th): Genomics and Personalized Medicine Act of 2010. http://www.govtrack.us/congress/ bills/111/ hr5440/text (Accessed: May 15, 2012).
3. Pruthi S, Gostout BS, Lindor NM. Identification and Mana gement of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc 2010; 85: 1111-20
4. Palma M, Ristori E, Ricevuto E, Giannini G, Gulino A. BRCA1 and BRCA2: The genetic testing and the current management options for mutation carriers. Crit Rev Oncol Hematol 2006; 57: 1-23
5. Baselga J, Rosen N. Determinants of RASistance to antiepidermal growth factor receptor agents. J Clin Oncol 2008; 26: 1582-4
6. Vogel F, Jager P. The genetic load of a human population due to cytostatic agents. Humangenetik 1969; 7: 287-304
7. Weinshilboum RM, Wang L. Pharmacogenetics and phar ma c ogenomics: Development, science, and translation. Annu Rev Genomics Hum Genet 2006; 7: 223-45
8. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75
9. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62
10. Kongkaew C, Noyce PR, Ashcroft DM. Hospital Admissions Associated with Adverse Drug Reactions: A Systematic Review of Prospective Observational Studies. The Annals of Pharmacotherapy 2008; 42: 1017-25
11. Beijer HJ, de Blaey CJ. Hospitalizations caused by adverse drug reactions (ADR): A meta-analysis of observational studies. Pharm World Sci 2002; 24: 46-54
12. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
13. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45: 301-8
14. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19
15. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7: 201-4
16. Mallal S, Phillips E, Carosi G, Molina JM, Work man C, Tomazic J, Jagel-Guedes E, Rugina S, Kozy rev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. HLA-B. 5701 screening for hyper sensitivity to abacavir. N Engl J Med 2008; 358: 568-79
17. Chung,WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004; 428: 486
18. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmaco genet Genomics 2006; 16: 297-306
19. Wu AHB, Babić N, Yeo K-TJ. Implementation of pharmacogenomics into the clinical practice of therapeutics: Issues for the clinician and the laboratorian. Personalized Medicine 2009; 6: 315-27
20. Babić N, Haverfield EV, Burrus JA, Lozada A, Das S, Yeo KT. Comparison of performance of three commercial platforms for warfarin sensitivity genotyping. Clin Chim Acta 2009; 406: 143-7
21. Wade, N. Cost of decoding a genome is lowered. New York Times 2009
22. Staff B-IW. Illumina announces $5,000 genome pricing. Bio IT News 2011
23. Grossman I. Routine pharmacogenetic testing in clinical practice: Dream or reality? Pharmacogenomics 2007; 8: 1449-59
24. Valdes R, Payne D, Linder M. Guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice, National Academy of Clinical Biochemistry Laboratory Medicine Practice Gui delines. http://www.aacc.org/members/nacb/LMPG/Online Guide/PublishedGuidelines/ LAACP/Documents/PGx-Gui delines.pdf (Accessed: May 17, 2012).
25. CYP2D6 allele nomenclature. http://www. cypal leles.ki. se/cyp2d6.htm (Accessed: May 15, 2012).
26. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234-42
27. Pekmezović T. Gene-environment interaction: A Geneticepidemiological approach. Journal of Medical Bio chemistry 2010; 29: 131-4
28. Novaković I, Maksimović N, Cvetković S, Cvetković D. Gene polymorphisms as markers of disease susceptibility. Journal of Medical Bio chem istry 2010; 29: 135-8
29. Anderson JL, Horne BD, Stevens SM, Woller SC, Sa muelson KM, Mansfield JW, Robinson M, Barton S, Brunisholz K, Mower CP, Huntinghouse JA, Rollo JS, Siler D, Bair TL, Knight S, Muhlestein JB, Carlquist JF. A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) / Clinical Perspective. Circulation 2012; 125: 1997-2005
30. The Case for Personalized Medicine. http://www. personalizedmedicinebulletin. com/files/2011/11/Case-for-M-3rd-edition1.pdf (Accessed: May 15, 2012).